This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción TYME
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Tyme Technologies, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$1.14 |
| 52 Week Low | US$0.22 |
| Beta | 0.92 |
| 1 Month Change | -6.70% |
| 3 Month Change | 15.07% |
| 1 Year Change | -69.84% |
| 3 Year Change | -82.04% |
| 5 Year Change | -94.16% |
| Change since IPO | -94.08% |
Noticias y actualizaciones recientes
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05
Recent updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05TYME stock surges on merger agreement and Syros Pharmaceuticals
Jul 05Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Mar 19Tyme Technologies Offers Incredible Risk-Reward
Dec 07Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Nov 19Tyme Technologies: The Market Missed The Bullish Memo
Aug 27We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate
Jul 19Tyme Technologies reports FY results
Jun 10Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount
May 29Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Mar 26Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?
Feb 19
Tyme falls after equity offer as quarterly data indicate liquidity pressure
Feb 04Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections
Feb 03Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Feb 02Revisiting Tyme Technologies
Dec 17Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?
Dec 16Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?
Dec 09Tyme Technologies names new finance chief
Nov 30Rentabilidad de los accionistas
| TYME | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 26.9% | 4.7% | 0.7% |
| 1Y | -69.8% | 2.7% | 23.9% |
Rentabilidad vs. Industria: TYME underperformed the US Biotechs industry which returned -28% over the past year.
Rentabilidad vs. Mercado: TYME underperformed the US Market which returned -18.6% over the past year.
Volatilidad de los precios
| TYME volatility | |
|---|---|
| TYME Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: TYME has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: TYME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 13 | Richie Cunningham | www.tymeinc.com |
Resumen de fundamentos de Tyme Technologies, Inc.
| Estadísticas fundamentales de TYME | |
|---|---|
| Capitalización bursátil | US$53.50m |
| Beneficios(TTM) | -US$24.19m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-2.2x
Ratio precio-beneficio (PE)¿Está TYME sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TYME | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$24.19m |
| Beneficios | -US$24.19m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.14 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado TYME a largo plazo?
Ver rendimiento histórico y comparativa